TP53 and cancer: However, mutations in DDR genes related to cancer such as TP53, PPM1D, and CHEK2 impairs cell death process which should be normally activated upon DNA damage, leading to a hematopoietic stem cell survival advantage in the setting of cytotoxic drugs [23, 24].